Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour
European Journal of Cancer2017Vol. 76, pp. 84–92
Citations Over TimeTop 10% of 2017 papers
Silvia Stacchiotti, Maristella Saponara, Roberta Frapolli, Monica Tortoreto, Denis Cominetti, Salvatore Provenzano, Tiziana Negri, Gian Paolo Dagrada, Alessandro Gronchi, Chiara Colombo, Bruno Vincenzi, Giuseppe Badalamenti, Valentina Zuco, Salvatore Lorenzo Renne, Paola Collini, Carlo Morosi, Angelo Paolo Dei Tos, Ezia Bello, S. Pilotti, Paolo G. Casali, Maurizio D’Incalci, Nadia Zaffaroni
Related Papers
- → Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin(2017)61 cited
- → Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study(2019)41 cited
- → Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?(2017)15 cited
- → Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden(2013)12 cited
- → An effective treatment of a late-line trabectedin for relapsed leiomyosarcoma(2017)